Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction

Camila H Coelho; Rino Rappuoli; Peter J Hotez; Patrick E Duffy

doi:10.1016/j.pt.2019.04.008

Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction

Trends Parasitol. 2019 Jul;35(7):483-486. doi: 10.1016/j.pt.2019.04.008. Epub 2019 May 29.

Authors

Camila H Coelho¹, Rino Rappuoli², Peter J Hotez³, Patrick E Duffy⁴

Affiliations

¹ Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA. Electronic address: camila.coelho@nih.gov.
² GlaxoSmithKline, Via Fiorentina 1, 53100 Siena, Italy.
³ Texas Children's Hospital Center for Vaccine Development, Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
⁴ Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA. Electronic address: patrick.duffy@nih.gov.

PMID: 31153722
DOI: 10.1016/j.pt.2019.04.008

Abstract

Malaria kills more than 600 000 people yearly, mainly children, and eradication is a global priority. Malaria transmission-blocking vaccines are advancing in clinical trials, and strategies for their introduction must be prioritized among stakeholders and the vulnerable populations exposed to the disease.

Keywords: low-income countries; malaria vaccines; transmission-blocking vaccines; vaccine introduction.

Published by Elsevier Ltd.

Publication types

Research Support, N.I.H., Intramural
Review

MeSH terms

Clinical Trials as Topic
Humans
Malaria / prevention & control*
Malaria / transmission
Malaria Vaccines / standards*
Plasmodium falciparum / immunology
Protozoan Proteins / immunology
Vulnerable Populations

Substances

Malaria Vaccines
Protozoan Proteins